Trial Profile
A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs CV 301 (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folic acid; Oxaliplatin
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- 21 Jan 2023 Status changed to discontinued , according to Results presented at the 2023 Gastrointestinal Cancers Symposium
- 21 Jan 2023 Preliminary efficacy and correlative results presented at the 2023 Gastrointestinal Cancers Symposium
- 18 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.